Indivior (NASDAQ:INDV) Shares Rise 4.7% - What's Next for Investors?

On Tuesday, shares of Indivior PLC (NASDAQ:INDV) saw a notable increase of 4.7% during mid-day trading. The stock peaked at $9.95 and settled at a price of $9.99 by the end of the session. A total of 376,723 shares exchanged hands, which is significantly lower, by 65%, than the average trading volume of 1,087,194 shares. The previous day's closing price was $9.54.

Analyst Insights

Recently, several analysts have provided their perspectives on Indivior. Notably, RODMAN & RENSHAW upgraded the stock to a "strong-buy" rating in a report dated January 28. Piper Sandler also maintained an "overweight" rating while increasing their price target for Indivior from $15.00 to $16.00 in a report on October 25. Additionally, Rodman & Renshaw initiated coverage of Indivior, assigning a "buy" rating alongside a $16.00 price target.

Stock Performance Overview

Indivior has a market capitalization of $1.38 billion, with a price-to-earnings (P/E) ratio of -250.81 and a beta value of 0.73. The stock has averaged $11.73 over the past fifty days, while its 200-day moving average stands at $11.03.

Institutional Investment Trends

In recent months, several institutional investors have adjusted their stakes in Indivior. Among them, Mirae Asset Global Investments Co. Ltd. acquired a new stake in the fourth quarter, valued at approximately $56,000. Stifel Financial Corp. and Melqart Asset Management UK Ltd. also made new investments in the third quarter, valued at about $100,000 and $132,000, respectively. Additionally, Jane Street Group LLC and Public Employees Retirement System of Ohio bought new positions valued at $180,000 and $294,000, respectively. Currently, institutional and hedge funds hold 60.33% of the company’s total shares.

Company Overview

Indivior PLC specializes in the development, manufacturing, and distribution of buprenorphine-based prescription medications primarily aimed at treating opioid dependence and related mental health disorders. The company operates both in the United States and internationally, focusing on the treatment of substance use disorders and other serious mental health issues.

Investment Consideration

For potential investors, while Indivior holds a "Buy" rating from many analysts, there are other stocks that may be recommended as better investments. It's important for investors to conduct thorough research before making decisions based on analyst ratings.

Indivior, Stocks, Analysts